GANX — Gain Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1819411 ·
Last close
$1.05
Market Cap
$46.75M
52W High
$4.34
52W Low
$0.94
ADV30
688,601
Next earnings
—
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,203,132 -3,160,408 13,231,887 11,697,570 3,081,231
Jun 2026 0 — -4,681,652 -4,675,571 15,421,939 13,084,144 4,129,908
Mar 2026 0 — -5,353,545 -5,608,732 18,738,464 16,539,222 4,731,487
Dec 2025 0 — -4,466,023 -4,537,581 22,818,975 20,837,628 4,254,227

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,952,455
Investing CF
$0
Financing CF
$25,354,389
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.58
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-111,640,310
Inventory
—
Receivables
$1,031,706
ST Investments
—
EBIT TTM
$-19,286,997
Pretax Income TTM
$-19,199,717
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -18,710,702 -20,161,099 22,818,975 4,254,227 18,564,748 -18,465,432
Dec 2024 0 -20,350,592 -20,411,191 12,123,884 4,784,310 7,339,574 -18,873,827
Dec 2023 55,180 -22,253,133 -22,267,520 18,609,331 6,031,107 12,578,224 -18,865,873
Dec 2022 140,108 -17,777,045 -17,590,738 24,099,387 5,219,873 18,879,514 -14,692,139
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-38,573,994
NetIncome TTM
$-20,106,257
OpCashFlow TTM
—
Assets (Latest)
$15,421,939
Forward EPS
$-0.60

Max Pain — expiry 2027-02-19

max pain strike: $1.00 · spot: $1.05 · call oi: 2,305 · put oi: 93
Expected Move to 2027-02-19: ±$0.56 (53.81%) — implied range $0.49 – $1.61 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RFL Rafael Holdings, Inc. $46.26M $0.90 —
HOWL Werewolf Therapeutics, Inc. $47.90M $0.99 —
SPRO Spero Therapeutics, Inc. $48.14M $0.83 —
QUCY Quantum Cyber N.V. $48.16M $0.55 —
PDSB PDS Biotechnology Corp $45.19M $0.81 —

News headlines (Yahoo Finance, 1h cache)

Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
2026-11-17 21:15 · Yahoo
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
2026-11-16 16:00 · Yahoo
Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
2026-11-10 12:00 · Yahoo
Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
2026-11-05 12:00 · Yahoo
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
2026-10-08 11:00 · Yahoo
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
2026-10-01 13:28 · Yahoo
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
2026-09-29 21:50 · Yahoo
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
2026-09-17 11:00 · Yahoo
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
2026-08-25 11:00 · Yahoo
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
2026-07-16 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.